Prognostic factors of early recurrence after complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

BACKGROUND Although cytoreductive surgery(CRS)and hyperthermic intraperitoneal chemotherapy(HIPEC)offer the potential for long-term survival in peritoneal carcinomatosis,outcomes following CRS/HIPEC vary significantly.AIM To identify the clinical factors associated with progression-free survival(PFS)after complete CRS/HIPEC in patients with colorectal/high-grade appendiceal,ovarian,and gastric cancers.METHODS We retrospectively evaluated the risk of recurrence within 1 year after CRS/HIPEC and its impact on overall survival(OS)in patients recruited between 2015 and 2020.Logistic regression models were used to assess the prognostic factors for the risk of recurrence within 1 year.Kaplan–Meier survival curves and Cox proportional hazards models were used to evaluate the association between recurrence and OS.RESULTS Of the 80 enrolled patients,39 had an unfavorable PFS(<1 year)and 41 had a favorable PFS(≥1 year).Simple logistic models revealed that the patients with a completeness of cytoreduction score of 0(CC-0)or length of CRS≤6 h had a favorable PFS[odds ratio(OR)=0.141,P=0.004;and OR=0.361,P=0.027,respectively].In multiple logistic regression,achieving CC-0 was the strongest prognostic factor for a favorable PFS(OR=0.131,P=0.005).A peritoneal cancer index score>12 was associated with a lower rate of achieving CC-0(P=0.027).The favorable PFS group had a significantly longer OS(median 81.7 mo vs 17.0 mo,P<0.001).CONCLUSION Achieving CC-0 was associated with a lower early recurrence rate and improved long-term survival.This study underscores the importance of selecting appropriate candidates for CRS/HIPEC to manage peritoneal carcinomatosis.

Analysis of therapeutic effect of cell reduction combined with intraperitoneal thermoperfusion chemotherapy in treatment of peritoneal pseudomyxoma

BACKGROUND Pseudomyxoma peritonei is a rare tumor that can produce a biological behavior similar to that of a malignant tumor.Surgical resection combined with chemo-therapy is the traditional treatment method,but the effect is not good.Cell reduction(CRS)combined with intraperitoneal thermoperfusion chemotherapy(HIPEC)has become a new method for the treatment of peritoneal pseudomy-xoma(PMP).AIM To find out if CRS and HIPEC can be used safely and effectively to treat PMP.METHODS This is an observational study.Clinical data of PMP patients treated with CRS+HIPEC at our hospital from January 2013 to June 2023 was collated and analyzed.The main outcome measures were overall survival(OS),and the secondary outcome measures were the incidence of surgical complications and serious adverse events.Complications were graded according to common adverse event evaluation criteria.Peritoneal tumor staging was performed using the peritoneal tumor index(PCI)scoring system,and a cell reduction degree(CCR)score was performed after CRS.CCR-0 and CCR-1 were considered satisfactory CRS.RESULTS A total of 186 patients with PMP were included,with a median age of 56(48-64)years,65(34.9%)years in males,and 121(65.1%)years in females.The median PCI score was 28(20-34)points.The median operative time was 300(211-430)minutes,and no significant complications occurred.91.4%(170/186)were from the appendix,53.2%(99/186)were from the low grade,and 30.6%(57/186)were from the high grade.CCR scores showed that 55 patients(29.6%)achieved satisfactory CRS,and 113 patients(60.8%)did not achieve satisfactory CRS.The fatality rate at 30 days after surgery was 2.7%(5/186),1.6%(3/186)needed a second operation,and the fatality rate at 90 days was 4.3%(8/186).The total incidence of III-IV complications was 43.0%(80/186),among which the higher incidence was mainly anemia(27.4%,51/186),electrolyte disturbance(11.6%,21/181),and albumin decrease(7.5%,14/186).The main compli-cations associated with abdominal surgery were gastrointestinal anastomotic leakage(2.2%,4/186),abdominal hemorrhage(2.2%,4/186),and abdominal infection(4.3%,8/186).The median follow-up was 38.1(95%CI:31.2-45.1)months.The 5-year OS of PMP patients treated with CRS+HIPEC was 50.3%(95%CI:40.7%-59.9%),and the median survival time was 66.1(95%CI:43.1-89.1)months.The results of the survival analysis showed that patients with a low pathological grade,a low PCI,and a satisfactory CCR score had a higher survival rate(all P<0.05).5-year OS was 88.9%(95%CI:68.3%-100.0%)in CCR-0 patients,77.6%(95%CI:62.7%-92.5%)in CCR-1 patients,and 42.0%(95%CI:29.5%-54.5%)in CCR-2/3 patients.CONCLUSION The application of CRS+HIPEC in PMP is safe and feasible,and the survival benefit is high,especially in those who achieve satisfactory CRS,which can significantly extend the OS.

Tuberculous peritonitis complicated by an intraperitoneal tuberculous abscess: A case report

BACKGROUND Tuberculous peritonitis(TBP)is a chronic,diffuse inflammation of the peritoneum caused by Mycobacterium tuberculosis.The route of infection can be by direct spread of intraperitoneal tuberculosis(TB)or by hematogenous dissemination.The former is more common,such as intestinal TB,mesenteric lymphatic TB,fa-llopian tube TB,etc.,and can be the direct primary lesion of the disease.CASE SUMMARY We present an older male patient with TBP complicated by an abdominal mass.The patient's preoperative symptoms,signs and imaging data suggested a poss-ible abdominal tumor.After surgical treatment,the patient's primary diagnosis of TBP complicating an intraperitoneal tuberculous abscess was established by com-bining past medical history,postoperative pathology,and positive results of TB-related laboratory tests.The patient's symptoms were significantly reduced after surgical treatment,and he was discharged from the hospital with instructions to continue treatment at a TB specialist hospital and to undergo anti-TB treatment if necessary.CONCLUSION This case report analyses the management of TBP complicated by intraperitoneal tuberculous abscess and highlights the importance of early definitive diagnosis in the hope of improving the clinical management of this type of disease.

Impact of hyperthermic intraperitoneal chemotherapy on gastric cancer survival: Peritoneal metastasis and cytology perspectives

BACKGROUND Gastric cancer presenting with peritoneal metastasis is notably associated with diminished survival prospects.The use of cytoreductive surgery in conjunction with hyperthermic intraperitoneal chemotherapy(HIPEC)has been shown to increase survival rates in these patients.Despite these advancements,debates persist regarding the magnitude of survival improvement attributed to this treatment modality.The present investigation examined survival outcomes following HIPEC in individuals diagnosed with gastric cancer and peritoneal metastasis,and it took a comparative analysis of patients exhibiting positive and negative cytological findings.Between April 2013 and March 2020,84 patients with advanced gastric cancer treated at our institution were categorized into three cohorts:HIPEC(20 patients with peritoneal metastasis),cytology-positive(23 patients without peritoneal nodules but with positive wash cytology),and cytology-negative(41 patients with advanced gastric cancer,no peritoneal nodules,and negative wash cytology).The HIPEC cohort underwent gastrectomy with HIPEC,while the cytology-positive and cytology-negative groups received gastrectomy alone.The demographic,pat-hological,and survival data of the groups were compared.RESULTS The HIPEC cohort-predominantly younger females-exhibited relatively extended surgical durations and high blood loss.Nevertheless,the complication rates were consistent across all three groups.Median survival in the HIPEC group was 20.00±4.89 months,with 1-year,2-year,and 3-year overall survival rates of 73.90%,28.70%,and 9.60%,respectively.These figures paralleled the survival rates of the cytology-positive group(52.20%at 1 year,28.50%at 2 years,and 19.00%at 3 years).Notably,47%of patients experienced peritoneal recurrence.CONCLUSION HIPEC may offer a modest improvement in short-term survival for patients with gastric cancer and peritoneal metastasis,mirroring the outcomes in cytology-positive patients.However,peritoneal recurrence remained high.

Antineoplastic Effect of Calcium Channel Blocker-Verapamil and 5-Fluorouracil Intraperitoneal Chemotherapy on Hepatocarcinoma-Bearing Rats

Objective To study the antineoplastic effect of the calcium channel blocker verapamil and 5-fluorouracil intraperitoneal chemotherapy onhepatocarcinoma-bearing rats, and examine the action between calcium channel blockers and cytotoxic drugs.Methods We adopted the method of subcapsular implantation of carcinoma tissues of walker-256 in the left liver lobe as a model of livercarcinoma-bearing rats. All experimental animals were divided into four groups. On the sixth day post implantation, in group A (controlgroup) 6 ml of saline was injected intraperitoneally once a day for 3 days. In group B (single chemotherapy group) 6 ml of 5-Fu 75 mg/kg was injected intraperitoneally once a day for 3 days. In group C (combination of treatment group) both 5-Fu (75 mg/kg) and verapamil(25 mg/kg) were administered simultaneously as in A and B. In group D (simple verapamil group) only 6 ml of verapamil (25 mg/kg)was administered as above.Results Compared with groups A, B and D, The volume of cancer and the contents of liver cancer DNA and protein were significantlyreduced. The rates of inhibiting cancer (89.9% in group C and 35.4% in group B) were significantly increased in group C. Group C hadsignificantly long survival time compared to groups A, B and D ( P < 0.05) . By light microscopy, a number of focal necroses were foundin cancer tissue in group C.Conclusion Calcium channel blockers can enhance the antineoplastic effect of 5-Fu intraperitoneal chemotherapy to liver cancer ; Theuse of verapamil can not increase the toxicity of 5-Fu.

考虑碳-绿证市场耦合的多虚拟电厂电-碳P2P交易模型

为了探索多市场交易下虚拟电厂(VPP)之间的点对点(P2P)交易模式,提出一种考虑碳-绿证市场耦合的多VPP电-碳P2P交易模型。建立包含光伏、储能、中央空调、碳捕集机组和用户负荷的多VPP聚合模型,建立绿证-碳配额耦合的VPP交易模型;在此基础上,基于合作博弈理论,建立多VPP社会效益最大化模型,采用交替方向乘子法对模型进行分布式求解,并建立非对称纳什议价模型对合作剩余利润进行分配;通过算例分析验证所提模型能在提升经济效益的同时,减少VPP的CO_(2)排放量。

真武汤介导lncRNA NEAT1/miR-31-5p/IGFBP7分子轴抑制慢性心力衰竭进程的机制研究

目的:探讨真武汤通过lncRNA NEAT1/miR-31-5p/IGFBP7分子轴抑制慢性心力衰竭(CHF)进程的机制。方法:将雄性SD大鼠分为对照组、模型组、阳性对照组和真武汤低、中、高剂量组,每组各10只。除对照组外,其余各组采用腹腔注射阿霉素的方法建立CHF模型,阳性对照组给予美托洛尔灌胃,真武汤低、中、高剂量组给予真武汤(生药含量6、12、18 g/kg)灌胃。检测各组大鼠左心室射血分数(LVEF)、左心室短轴缩短率(LVFS),血清脑钠肽(BNP)水平,心脏体重比,心肌病理改变,心肌中肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)、丙二醛(MDA)、超氧化物歧化酶(SOD)水平及lncRNA NEAT1、miR-31-5p、IGFBP7表达水平。培养大鼠心肌H9c2细胞,采用双荧光素酶报告基因实验检测lncRNA NEAT1靶向miR-31-5p、miR-31-5p靶向IGFBP7。结果:与模型组比较,真武汤低、中、高剂量组的LVEF、LVFS增加,血清BNP水平降低(P<0.05);与模型组比较,真武汤低、中、高剂量组的心肌TNF-α、IL-1β、MDA水平降低,SOD水平增加(P<0.05);与模型组比较,真武汤低、中、高剂量组的心肌lncRNA NEAT1、IGFBP7表达降低,miR-31-5p表达增加(P<0.05)。H9c2心肌细胞中,lncRNA NEAT1靶向miR-31-5p、miR-31-5p靶向IGFBP7。结论:真武汤可能通过lncRNA NEAT1/miR-31-5p/IGFBP7分子轴改善CHF大鼠心功能并减轻炎症反应、氧化应激反应。

基于可选休假和优先权Geo/G/1重试排队的P2P网络分析

该文旨在根据P2P网络中节点状态的动态变化,构建一个排队模型,以精确模拟节点在系统中的动态趋势.基于这一模型框架,建立了一个带二次可选休假、优先权和不耐烦请求节点的Geo/G/1重试排队系统.利用嵌入Markov链的方法,构造相应维数的Markov链,分析网络系统中各个节点状态的一步转移概率;利用补充变量法推导系统满足的平衡方程组,通过求解平衡方程组得到网络系统中各类节点的性能指标.通过调整不同参数,验证系统的性能指标随参数的变化趋势.

PTEN及ERG在前列腺导管内癌中表达的意义研究

目的探讨PTEN缺失和ERG阳性表达在前列腺导管内癌(IDC-P)发生发展过程中的意义。方法收集45例IDC-P作为观察组,60例无IDC-P区域的前列腺癌(Gleason评分≥7)作为对照组,分别进行ERG和PTEN免疫组化染色,对比ERG和PTEN蛋白在两组病例中的表达频率。结果观察组IDC-P及其邻近的前列腺癌中PTEN缺失和ERG阳性表达率比较,差异无统计学意义(P>0.05),相邻前列腺癌PTEN缺失,IDC-P区域PTEN也缺失,相邻前列腺癌ERG阳性表达,IDC-P区域ERG也阳性表达;观察组中PTEN缺失频率显著高于对照组(P<0.05),两组中ERG阳性表达频率差异无统计学意义(P>0.05),观察组中PTEN缺失合并ERG阳性表达的频率显著高于对照组(P<0.05);观察组不同肿瘤T分期组中PTEN缺失及ERG阳性表达率比较,差异有统计学意义(P<0.05),而不同肿瘤Gleason评分、前列腺外扩展、精囊腺侵犯、淋巴结转移及生化复发分组中的表达率比较,差异无统计学意义(P>0.05)。结论IDC-P是相邻浸润性前列腺癌沿导管扩散浸润的过程,PTEN缺失与ERG阳性表达可能促进这一过程,且两者相互作用,共同促进IDC-P的发生发展,PTEN及ERG有望成为IDC-P临床管理的参考指标及治疗的靶点。

基于P3HT的有机薄膜晶体管环境稳定性提升

电子设备领域对高稳定性有机薄膜晶体管(OTFT)的需求日益增长。为了解决有机材料在环境因素作用下影响晶体管稳定性的问题,制备了一种新型OTFT,并同时采用两种方法来提高其环境稳定性:对晶体管进行表面钝化处理,利用钝化层的高化学稳定性隔绝空气中的氧分子和水分子;利用聚(3-己基噻)(P3HT)共混聚甲基丙烯酸甲酯(PMMA)有源层获得高抗氧化性和抗水解能力。测试结果表明,经过60d后器件载流子迁移率仅降低到原始值的87.91%,电流开关比降低到原来的81.90%,说明本文提出的环境稳定性提升方法优于其他方法。

Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites

AIM:To investigate the procedure, feasibility and effects of laparoscopeassisted continuous circulatory hyperthermic intraperitoneal perfusion chemotherapy (CHIPC) in treatment of malignant ascites induced by peritoneal carcinomatosis from gastric cancers. METHODS: From August 2006 to March 2008, the laparoscopic approach was used to perform CHIPC on 16 patients with malignant ascites induced by gastric cancer or postoperative intraperitoneal seeding. Each patient underwent CHIPC three times after laparoscopeassisted perfusion catheters placing. The first session was completed in operative room under general anesthesia, 5% glucose solution was selected as perfusion liquid, and 1500 mg 5 fluorouracil (5FU) and 200 mg oxaliplatin were added in the perfusion solution. The second andthird sessions were performed in intensive care unit, 0.9% sodium chloride solution was selected as perfusion liquid, and 1500 mg 5FU was added in the perfusion solution alone. CHIPC was performed for 90 min at a velocity of 450600 mL/min and an in flow temperature of 43 ± 0.2℃.RESULTS: The intraoperative course was uneventful in all cases, and the mean operative period for laparoscopeassisted perfusion catheters placing was 80 min for each case. No postoperative deaths or complications related to laparoscopeassisted CHIPC occurred in this study. Clinically complete remission of ascites and related symptoms were achieved in 14 patients, and partial remission was achieved in 2 patients. During the followup, 13 patients died 29 mo after CHIPC, with a median survival time of 5 mo. Two patients with partial remission suffered from port site seeding and tumor metastasis,and died 2 and 3 mo after treatment. Three patients who are still alive today survived 4, 6 and 7 mo, respectively. The Karnofsky marks of patients (5090) increased significantly (P < 0.01) and the general status improved after CHIPC. Thus satisfactory clinical efficacy has been achieved in these patients treated by laparoscopic CHIPC. CONCLUSION: Laparoscopeassisted CHIPC is a safe, feasible and effective procedure in the treatment of debilitating malignant ascites induced by unresectable gastric cancers.

Regional but fatal: Intraperitoneal metastasis in gastric cancer

Peritoneal carcinomatosis appears to be the most common pattern of metastasis or recurrence and is associated with poor prognosis in gastric cancer patients. Many efforts have been made to improve the survival in patients with peritoneal metastasis. Hyperthermic intraperitoneal chemotherapy remains a widely accepted strategy in the treatment of peritoneal dissemination. Several phase Ⅱ-Ⅲ studies confirmed that the combined cytoreducitve surgery and hyperthermic intraperitoneal chemotherapy resulted in longer survival in patients with peritoneal carcinomatosis. In addition,proper selection and effective regional treatment in patients with high risk of peritoneal recurrence after resection will further improve prognosis in local advanced gastric cancer patients.

Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies

Locoregional spread of abdominopelvic malignant tumors frequently results in peritoneal carcinomatosis(PC). The prognosis of PC patients treated by conventional systemic chemotherapy is poor, with a median survival of < 6 mo. However, over the past three decades, an integrated treatment strategy of cytoreductive surgery(CRS) + hyperthermic intraperitoneal chemotherapy(HIPEC) has been developed by the pioneering oncologists, with proved efficacy and safety in selected patients. Supported by several lines of clinical evidence from phases Ⅰ, Ⅱ and Ⅲ clinical trials, CRS + HIPEC has been regarded as the standard treatment for selected patients with PC in many established cancer centers worldwide. In China, an expert consensus on CRS + HIPEC has been reached by the leading surgical and medical oncologists, under the framework of the China Anti-Cancer Association. This expert consensus has summarized the progress in PC clinical studies and systematically evaluated the CRS + HIPEC procedures in China as well as across the world, so as to lay the foundation for formulating PC treatment guidelines specific to the national conditions of China.

长链非编码RNA LINC00926调控微小RNA-331-3p对前列腺癌细胞增殖和迁移的影响

目的:探讨长链非编码RNA(lncRNA)LINC00926对前列腺癌细胞增殖和迁移的影响及分子机制。方法:前列腺癌组织和癌旁组织LINC00926表达用LncRNADisease数据库分析。采用RT-qPCR检测正常前列腺上皮RWPE-1细胞和前列腺癌细胞株22Rv1、PC3、C4-2B、LNCaP、DU-145中LINC00926的表达。选取LINC00926表达最高的前列腺癌DU-145细胞,分别转染LINC00926小干扰RNA(si-LINC00926组)和阴性对照RNA(si-NC组)。采用CCK-8法、划痕实验检测DU-145细胞增殖和迁移能力。双荧光素酶报告基因实验检测LINC00926与miR-331-3p的靶向结合。采用RT-qPCR检测DU-145细胞中miR-331-3p表达。采用Western blot检测Wnt/β-连环蛋白(β-catenin)信号通路相关蛋白表达。结果:前列腺癌组织LINC00926表达水平高于癌旁组织(P<0.05)。与RWPE-1细胞比较,LINC00926在前列腺癌22Rv1、PC3、DU-145、C4-2B、LNCaP细胞中表达水平升高,且DU-145细胞表达最高(均P<0.05)。si-NC组LINC00926表达水平高于si-LINC00926组(P<0.05)。于24、48、72、96 h,si-LINC00926组DU-145细胞增殖能力低于si-NC组(均P<0.05)。与si-NC组比较,si-LINC00926组DU-145细胞迁移能力下降(P<0.05)。LINC00926-WT和miR-331-3p共转染荧光素酶相对活性低于LINC00926-WT和miR-NC共转染(P<0.05)。si-NC组miR-331-3p表达水平低于si-LINC00926组(P<0.05)。与si-NC组比较,si-LINC00926组DU-145细胞中β-连环蛋白(β-catenin)、细胞髓细胞瘤病毒癌基因同源物蛋白(c-myc)、细胞周期蛋白D1(Cyclin D1)、周期蛋白依赖激酶3(CDK3)、B淋巴细胞瘤-2(Bcl-2)蛋白表达水平降低(均P<0.05)。结论:LINC00926在前列腺癌组织和细胞中高表达,下调LINC00926可能通过靶向miR-331-3p抑制前列腺癌细胞的增殖和迁移能力。

Effect of intraperitoneal local anesthetic on pain characteristics after laparoscopic cholecystectomy

AIM : To systematically evaluate the effect of intraperitoneal local anesthetic on pain characteristics after laparoscopic cholecystectomy(LC).METHODS: We searched MEDLINE, EMBASE, and the Cochrane Library. Randomized controlled trials in English that compared the effect of intraperitoneal administration of local anesthetics on pain with that of placebo or nothing after elective LC under general anesthesia were included. The primary outcome variables analyzed were the combined scores of abdominal, visceral, parietal, and shoulder pain after LC at multiple time points. We also extracted pain scores at resting and dynamic states.RESULTS: We included 39 studies of 3045 patients in total. The administration of intraperitoneal local anesthetic reduced pain intensity in a resting state after laparoscopic cholecystectomy: abdominal [standardized mean difference(SMD) =-0.741; 95%CI:-1.001 to-0.48, P < 0.001]; visceral(SMD =-0.249; 95%CI:-0.493 to-0.006, P = 0.774); and shoulder(SMD =-0.273; 95%CI:-0.464 to-0.082, P = 0.097). Application of intraperitoneal local anesthetic significantly reduced the incidence of shoulder pain(RR = 0.437; 95%CI: 0.299 to 0.639, P < 0.001). There was no favorable effect on resting parietal or dynamic abdominal pain.CONCLUSION: Intraperitoneal local anesthetic as an analgesic adjuvant in patients undergoing laparoscopic cholecystectomy exhibited beneficial effects on postoperative abdominal, visceral, and shoulder pain in a resting state.

Intraperitoneal perfusion of cytokine-induced killer cells with local hyperthermia for advanced hepatocellular carcinoma

AIM:To study the effect and tolerance of intraperitoneal perfusion of cytokine-induced killer(CIK) cells in combination with local radio frequency(RF) hyperthermia in patients with advanced primary hepatocellular carcinoma(HCC).METHODS:Patients with advanced primary HCC were included in this study.CIK cells were perfused intraperitoneal twice a week,using 3.2 × 10 9 to 3.6 × 10 9 cells each session.Local RF hyperthermia was performed 2 h after intraperitoneal perfusion.Following an interval of one month,the next course of treatment was administered.Patients received treatment until disease progression.Tumor size,immune indices(CD3 +,CD4 +,CD3 + CD8 +,CD3 + CD56 +),alpha-fetoprotein(AFP) level,abdominal circumference and adverse events were recorded.Time to progression and overall survival(OS) were calculated.RESULTS:From June 2010 to July 2011,31 patients diagnosed with advanced primary HCC received intraperitoneal perfusion of CIK cells in combination with local RF hyperthermia in our study.Patients received an average of 4.2 ± 0.6 treatment courses(range,1-8 courses).Patients were followed up for 8.3 ± 0.7 mo(range,2-12 mo).Following combination treatment,CD4 +,CD3 + CD8 + and CD3 + CD56 + cells increased from 35.78% ± 3.51%,24.61% ± 4.19% and 5.94% ± 0.87% to 45.83% ± 2.48%(P = 0.016),39.67% ± 3.38%(P = 0.008) and 10.72% ± 0.67%(P = 0.001),respectively.AFP decreased from 167.67 ± 22.44 to 99.89 ± 22.05 ng/mL(P = 0.001) and abdominal circumference decreased from 97.50 ± 3.45 cm to 87.17 ± 4.40 cm(P = 0.002).The disease control rate was 67.7%.The most common adverse events were low fever and slight abdominal erubescence,which resolved without treatment.The median time to progression was 6.1 mo.The 3-,6-and 9-mo and 1-year survival rates were 93.5%,77.4%,41.9% and 17.4%,respectively.The median OS was 8.5 mo.CONCLUSION:Intraperitoneal perfusion of CIK cells in combination with local RF hyperthermia is safe,can efficiently improve immunological status,and may prolong survival in HCC patients.

Intraperitoneal chemotherapy and its evolving role in management of gastric cancer with peritoneal metastases

Advanced gastric cancer （GC） has been recognized as lethal disease when peritoneal metastases （PM） occurred.There is no standard treatment for advanced GC with PM.Until 1980s,the therapeutic arena for these patients had remained stagnant,with no therapeutic approach having shown a survival gain in GC with PM.However,cytoreductive surgery （CRS） with peritonectomy procedures and intraperitoneal chemotherapy （IPC） promising new combined therapeutic approach to achieve disease control for GC with PM.The recent publications changed the GC with PM treatment landscape by providing an evidence that CRS and IPC led to prolongation in overall survival （OS）.This review will provide an overview of the evolving role of CRS and IPC in the management of advanced GC with PM in the current era.

A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy

Perioperative intraperitoneal chemotherapy in combination with cytoreductive surgery has been shown to be of benefit for treating selected patients with peritoneal surface malignancy.It has become a new standard of care in the management of diffuse malignant peritoneal mesothelioma and peritoneal dissemination of appendiceal malignancy.Numerous recent publications on carcinomatosis from colorectal cancer and gastric cancer identify groups of patients that would benef it from this local-regional approach for prevention and treatment of carcinomatosis.This review focuses on pharmacological information regarding intraperitoneal chemotherapeutic agents commonly used in gastrointestinal oncology.

依托咪酯调控miR-204-5p/HOXC8轴对胃癌细胞增殖、凋亡及侵袭的影响

目的探讨依托咪酯(Eto)调节微小RNA(miR)-204-5p/同源盒基因C8(HOXC8)轴对人胃癌细胞增殖、凋亡及侵袭的影响。方法2023年4月—2024年4月于武汉科技大学实验室进行实验,将胃癌细胞MKN45分为对照(Ctrl)组、低剂量Eto组(Eto-L,5μmol/L)、中剂量Eto组(Eto-M,10μmol/L)、高剂量Eto组(Eto-H,20μmol/L)、Eto-H+miR-inhibitor-NC、Eto-H+miR-204-5p inhibitor组。CCK-8法、集落形成实验检测细胞增殖情况,流式细胞术检测MKN45细胞凋亡情况,Transwell实验检测细胞侵袭能力;qRT-PCR检测细胞中miR-204-5p和HOXC8 mRNA表达水平;双荧光素酶实验检测miR-204-5p和HOXC8之间的靶向关系。结果与Ctrl组比较,Eto-L组、Eto-M组、Eto-H组、Eto-H+miR-inhibitor-NC组、Eto-H+miR-204-5p inhibitor组MKN45细胞存活率、集落形成率、细胞侵入率、HOXC8 mRNA水平均显著降低(F/P=33.391/<0.001、29.646/<0.001、44.814/<0.001、45.485/<0.001),细胞凋亡率和miR-204-5p水平显著升高(F/P=78.091/<0.001、22.665/<0.001);与Eto-H+miR-inhibitor-NC组比较,Eto-H+miR-204-5p inhibitor组MKN45细胞存活率、集落形成率、细胞侵入率、HOXC8 mRNA水平均显著升高(q/P=8.099/<0.001、7.587/<0.001、7.768/<0.001、11.162/<0.001),细胞凋亡率和miR-204-5p水平显著降低(q/P=10.254/<0.001、8.596/<0.001);与HOXC8-WT和miR-NC共转染细胞比较,HOXC8-WT和miR-204-5p mimic共转染的MKN45细胞中相对荧光酶活性显著降低(t/P=5.770/<0.001)。结论Eto可能通过上调miR-204-5p、下调HOXC8,减弱胃癌细胞MKN45增殖和侵袭能力,促进细胞凋亡。

Injection of bone marrow mesenchymal stem cells by intravenous or intraperitoneal routes is a viable alternative to spinal cord injury treatment in mice

In spite of advances in surgical care and rehabilitation, the consequences of spinal cord injury （SCI） are still challenging. Several experimental therapeutic strategies have been studied in the SCI field, and recent advances have led to the development of therapies that may act on the inhibitory microenvironment. Assorted lineages of stem cells are considered a good treatment for SCI. This study investigated the effect of systemic transplantation of mesenchymal stem cells （MSCs） in a compressive SCI model. Here we present results of the intraperitoneal route, which has not been used previously for MSC administration after compressive SCI. We used adult female C57BL/6 mice that underwent laminectomy at the T9 level, followed by spinal cord compression for 1 minute with a 30-g vascular clip. The animals were divided into five groups： sham （anesthesia and laminectomy but without compression injury induction）, MSC i.p. （intraperitoneal injection of 8×10^5 MSCs in 500 μL of DMEM at 7 days after SCI）, MSC i.v. （intravenous injection of 8 × 10^5 MSCs in 500μL of DMEM at 7 days after SCI）, DMEM i.p. （intraperitoneal injection of 500μL of DMEM at 7 days after SCI）, DMEM i.v. （intravenous injection of 500 μL of DMEM at 7 days after SCI）. The effects of MSCs transplantation in white matter sparing were analyzed by luxol fast blue staining. The number of preserved fibers was counted in semithin sections stained with toluidine blue and the presence of trophic factors was analyzed by immunohistochemistry. In addition, we analyzed the locomotor performance with Basso Mouse Scale and Global Mobility Test. Our results showed white matter preservation and a larger number of preserved fibers in the MSC groups than in the DMEM groups. Furthermore, the MSC groups had higher levels of trophic factors （brain-derived neurotrophic factor, nerve growth factor, neurotrophin-3 and neurotrophin-4） in the spinal cord and improved locomotor performance. Our results indicate that injection of MSCs by either intraperitoneal or intravenous routes results in beneficial outcomes and can be elected as a choice for SCI treatment.